Want to see IN:COHANCE full AI Analyst Report?

Suven Pharmaceuticals Ltd. (COHANCE) Price & Analysis

3 Followers

COHANCE Stock Chart & Stats

₹891.10

₹6.60(0.60%)

At close: Jan 08 4:00 PM EST

₹891.10

₹6.60(0.60%)

Day’s Range― - ―

52-Week Range₹267.85 - ₹1,121.15

Previous CloseN/A

VolumeN/A

Average Volume (3M)116.47K

Market Cap

₹174.01B

Enterprise Value₹166.06B

Total Cash (Recent Filing)₹4.03B

Total Debt (Recent Filing)₹4.51B

Price to Earnings (P/E)67.1

Beta0.93

Next Earnings

Aug 07, 2026

EPS Estimate

0.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)9.70

Shares Outstanding382,567,140

10 Day Avg. Volume24,499

30 Day Avg. Volume116,469

Financial Highlights & Ratios

PEG Ratio-1.16

Price to Book (P/B)2.95

Price to Sales (P/S)5.08

P/FCF Ratio85.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹300.00

Price Target Upside-66.33% Downside

Rating ConsensusModerate Sell

Number of Analyst Covering1

EPS Forecast (FY)7.16

Revenue Forecast (FY)₹25.24B

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained top-line acceleration indicates stronger demand for Suven's services and larger project throughput. Higher revenue supports better capacity utilization and creates a base for converting development projects to recurring commercial manufacturing, improving long-term revenue visibility.

Conservative Balance SheetVery low leverage provides financial flexibility to fund capacity investments, absorb working-capital swings, and pursue client onboarding without immediate refinancing pressure. This resilience reduces bankruptcy and liquidity risk over the medium term.

Integrated CDMO CapabilitiesEnd-to-end capabilities and expertise in complex chemistry create high entry barriers and client stickiness. Offering R&D through commercial supply lets Suven capture more project lifecycle value and supports long-term contract conversion and margin stabilization when commercial volumes ramp.

Bears Say

Margin CompressionMaterial, sustained margin deterioration weakens earnings quality and reduces internal funds for reinvestment. If structural (mix shift or pricing pressure), lower margins heighten sensitivity to cost inflation and limit ability to invest in capacity or absorb contract renegotiations over the medium term.

Weaker Free Cash Flow ConversionDeclining FCF conversion constrains internal funding for capex, R&D, and working-capital needs central to CDMO growth. Persistently weak cash conversion increases reliance on external financing and limits flexibility to pursue larger commercial-scale projects or absorb client payment timing variability.

Rising Absolute DebtAn upward trend in absolute debt, even from low levels, raises fixed servicing obligations. If margins and cash generation remain impaired, higher debt could pressure liquidity, limit strategic investments, and increase refinancing or covenant risk across the 2–6 month horizon and beyond.

Suven Pharmaceuticals Ltd. News

Berhyanda affirms no new encumbrances on Cohance Lifesciences promoter shares for FY 2025-26

The latest update is out from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ). Berhyanda Limited, a promoter of Cohance...

13d ago

Cohance Lifesciences CFO and Whole-Time Director Himanshu Agarwal to Resign in September 2026

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has provided an update. Cohance Lifesciences Limited has announced that Himanshu Agarwal,...

19d ago

Cohance Lifesciences Says Volume Surge in Shares Is Market-Driven

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has shared an update. Cohance Lifesciences has responded to a query from...

3M ago

Cohance Lifesciences Appoints Sisir K. Mishra as Company Secretary and Compliance Officer

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has provided an announcement. Cohance Lifesciences has appointed Sisir K. Mishra as...

3M ago

Cohance Lifesciences Grants 198,711 Stock Options Under ESOP 2023

An announcement from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) is now available. Cohance Lifesciences has approved the grant...

4M ago

Cohance Lifesciences to Engage Investors at IIFL and Kotak Conferences in February 2026

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) just unveiled an announcement. Cohance Lifesciences Limited has announced that its management...

5M ago

COHANCE FAQ

What was Suven Pharmaceuticals Ltd.’s price range in the past 12 months?

Suven Pharmaceuticals Ltd. lowest stock price was ₹267.85 and its highest was ₹1121.15 in the past 12 months.

What is Suven Pharmaceuticals Ltd.’s market cap?

Suven Pharmaceuticals Ltd.’s market cap is ₹174.01B.

When is Suven Pharmaceuticals Ltd.’s upcoming earnings report date?

Suven Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 32 days.

How were Suven Pharmaceuticals Ltd.’s earnings last quarter?

Suven Pharmaceuticals Ltd. released its earnings results on May 12, 2026. The company reported ₹0.95 earnings per share for the quarter, missing the consensus estimate of ₹1.14 by -₹0.19.

Is Suven Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Suven Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suven Pharmaceuticals Ltd. pay dividends?

Suven Pharmaceuticals Ltd. pays a Notavailable dividend of ₹5 which represents an annual dividend yield of N/A. See more information on Suven Pharmaceuticals Ltd. dividends here

What is Suven Pharmaceuticals Ltd.’s EPS estimate?

Suven Pharmaceuticals Ltd.’s EPS estimate is 0.82.

How many shares outstanding does Suven Pharmaceuticals Ltd. have?

Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding.

What happened to Suven Pharmaceuticals Ltd.’s price movement after its last earnings report?

Suven Pharmaceuticals Ltd. reported an EPS of ₹0.95 in its last earnings report, missing expectations of ₹1.14. Following the earnings report the stock price went up 1.483%.

Which hedge fund is a major shareholder of Suven Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:COHANCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suven Pharmaceuticals Ltd.

Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.

Suven Pharmaceuticals Ltd. (COHANCE) Earnings & Revenues

Historic Earnings Reports

COHANCE Stock 12 Month Forecast

Average Price Target

₹300.00

▼(-66.33% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"299":"₹299","640":"₹640","981":"₹981","469.5":"₹469.5","810.5":"₹810.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹300.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹300.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹300.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[299,469.5,640,810.5,981],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,451.3,439.6615384615385,428.0230769230769,416.3846153846154,404.74615384615385,393.10769230769233,381.46923076923076,369.83076923076925,358.1923076923077,346.55384615384617,334.9153846153846,323.2769230769231,311.63846153846157,{"y":300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,451.3,439.6615384615385,428.0230769230769,416.3846153846154,404.74615384615385,393.10769230769233,381.46923076923076,369.83076923076925,358.1923076923077,346.55384615384617,334.9153846153846,323.2769230769231,311.63846153846157,{"y":300,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,451.3,439.6615384615385,428.0230769230769,416.3846153846154,404.74615384615385,393.10769230769233,381.46923076923076,369.83076923076925,358.1923076923077,346.55384615384617,334.9153846153846,323.2769230769231,311.63846153846157,{"y":300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":960.35,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":980.4,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":902.15,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":870.1,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":753.2,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":553.25,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":523.5,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":371,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":303.7,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":311.55,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":482.95,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":429.4,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":451.3,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >